Corixa Corp., of Seattle, appointed Chris Rivera vice president of sales.
Durect Corp., of Cupertino, Calif., appointed Jon Saxe to its board.
Guava Technologies Inc., of Hayward, Calif., added Kevin McCormack as director of European operations.
Human Genome Sciences Inc., of Rockville, Md., named Betsy Atkins and William Young to its board.
Idenix Pharmaceuticals Inc., of Cambridge, Mass., appointed Guy Macdonald executive vice president, operations.
ImClone Systems Inc., of New York, appointed Joseph Fischer to its board and audit committee.
Juvaris BioTherapeutics Inc., of Pleasanton, Calif., appointed Gene Mancino to its board.
Nastech Pharmaceutical Co. Inc., of Bothell, Wash., promoted Jade Brown to vice president of marketing and business development.
NeoStem Inc., of Agoura Hills, Calif., named Larry May chief financial officer.
Novactyl Inc., of St. Louis, named Mirza Beg senior clinical advisor.
Novogen Ltd., of Sydney, Australia, appointed Leanna Read a nonexecutive director.
Oncolytics Biotech Inc., of Calgary, Alberta, formed a scientific advisory board that includes Ramon Alemany, Richard Gorlick, Alan Tuchman and Frank Tufaro.
Parexel International Corp., of Boston, appointed Susan Alexander senior vice president and general counsel.
Praecis Pharmaceuticals Inc., of Waltham, Mass., elected Leonard Post to its board.
QuatRx Pharmaceuticals Co., of Ann Arbor, Mich., elected August Watanabe to its board.
Questcor Pharmaceuticals Inc., of Union City, Calif., added Jerald Beers as vice president, marketing and Stuart Weisman vice president, medical and regulatory affairs.
Raven Biotechnologies Inc., of South San Francisco, added Lucille Chang as vice president, manufacturing operations and Carolyn Adler as intellectual property and legal affairs.
Replidyne Inc., of Louisville, Colo., added Joseph Guiles as senior director of medicinal chemistry.
Senomyx Inc., of La Jolla, Calif., appointed Harry Leonhardt vice president and general counsel.
Structural Genomix Inc., of San Diego, appointed Stephen Wasserman director of X-ray technology.
Targacept Inc., of Winston-Salem, N.C., added Jeffrey Brennan as vice president, business and commercial development.
The Immune Response Corp., of Carlsbad, Calif., appointed Peter Salk to its scientific advisory board.
The Institute for Systems Biology in Seattle said its co-founder Ruedi Aebersold was appointed to the Swiss Federal Institute of Technology Zurich.
The National Institutes of Health in Bethesda, Md., appointed Brent Stanfield acting director of the Center for Scientific Review, effective Oct. 1.
TolerRx Inc., of Cambridge, Mass., added David McLachlan to its board.
Transkaryotic Therapies Inc., of Cambridge, Mass., promoted David Pendergast to executive vice president and chief operating officer.
Vivus Inc., of Mountain View, Calif., appointed Larry Strauss vice president, finance and chief financial officer.
ZymoGenetics Inc., of Seattle, added Fredrik Henell as senior vice president, business development.